Navigation Links
Analysis Shows Lamictal As An Effective Additional Therapy For Treatment of Grand Mal Seizures

Researchers have shown the effectiveness of Lamictal (lamotrigine) as additional treatment method in children and young people with primary// generalized tonic-clonic (PGTC) seizures.

According to the latest issue of the journal Paediatrics, lamotrigine (LAMICTAL) has been demonstrated to be effective as an additional therapy for the treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, in children and adolescents. It was explained that this research analysis is the first published data from a random, double blind, controlled clinical trial of PGTC seizures mainly concentrating on patients between the age group of 2 to 20 years. It was explained that 1C PGTC seizures, which are commonly know as "grand mal" seizures, are the most common form of generalized seizures, that occur in approximately 20% of patients with epilepsy. It was also mentioned that Lamictal is not presently indicated for the treatment of PGTC seizures.

'PGTC seizures are more common in children than in adults, and are associated with increased risk of injury or death,' said Edwin Trevathan, M.D., M.P.H., Director of the Division of Paediatric and Developmental Neurology at Washington University School of Medicine and Neurologist-in-Chief, St. Louis Children's Hospital, St. Louis, MO, key investigator of the clinical study. “These study findings are important since physicians and neurologists continue to have limited treatment options available for generalized seizures in this age group.”

PGTC seizures usually occur without warning and are associated with wide-ranging physical and behavioural changes with potentially life-threatening complications.

Patients who experience PGTC seizures become stiff, lose consciousness, and jerk repetitively. Patients may fall to the ground, bite their tongue, and/or lose bladder control. Serious injury including bone fractures can occur. The seizure will typically last for a few minutes and then be followed b y a period of drowsiness, confusion, headache, and sleep. For some people who have this type of seizure, it can take many hours to fully recover.

ABOUT THE STUDY
A randomised, double blind, placebo-controlled study was conducted to assess the efficacy and tolerability of adjunctive therapy with LAMICTAL in the treatment of PGTC seizures among patients 2 years of age and older. Investigators evaluated 117 patients, ages 2-55 years, with PGTC seizures inadequately controlled on 1-2 current AEDs and with evidence of PGTC seizures on electroencephalogram (EEG) and no past evidence of partial seizures. The treatment period consisted of an Escalation phase (7-12 weeks) and a Maintenance phase (12 weeks).

In a subgroup analysis of 45 patients 2-20 years of age, the median percent decrease from Baseline in PGTC seizures during the entire treatment period was 77 percent among patients receiving LAMICTAL and 40 percent in the placebo group (p=0.044). The median PGTC seizure counts per month were significantly improved for all treatment phases in patients receiving LAMICTAL compared to placebo.

The most commonly reported adverse events in this analysis were headache (10% LAMICTAL, 25% placebo), nasopharyngitis (14% LAMICTAL, 4% placebo), and convulsion (10% LAMICTAL, 17% placebo). One patient from each treatment group discontinued due to an adverse event. No serious rashes occurred among patients taking LAMICTAL or placebo. No patient experienced worsening of myoclonus.

Overall, adjunctive therapy with LAMICTAL appeared to be effective in controlling PGTC seizures among patients 2 to 20 years of age and was associated with a favourable tolerability profile.

ABOUT EPILEPSY
Epilepsy, defined by recurrent unprovoked seizures, is a change in sensation, awareness, or behaviour brought about by an electrical disturbance in the brain. The kind of seizure a person has depends on which part and how much of the brain is affected by the disturbance that produces seizures. Generalized seizures are seizures that involve the entire brain from the outset. In most cases, the cause of epilepsy is unknown. According to the Epilepsy Foundation, epilepsy affects more than 2.5 million people in the United States of all ages.

Source: EurekAler.
'"/>




Related medicine news :

1. Indian Scientists Make Wide-Ranging Analysis And Annotation Of X Chromosome
2. Meta Analysis Links Diabetes And Colorectal Cancer
3. NASA Analysis Say 2005 Was The Warmest Year
4. First Suspected Bird Flu Case In Serbia: Samples Sent For Analysis
5. A Detail Analysis of Head and Neck Cancer
6. Analysis: Bowel Diseases Triples Infertility Risks In Women
7. Analysis of Placenta Helps In Diagnosis of Autism At Birth
8. Salivary Analysis for Early Detection of Breast Cancer
9. Severe Complications of Circumcision: An Analysis of 48 Cases
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. New Prostate Cancer Vaccine Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... 12, 2017 , ... CitiDent and San Francisco dentists, Dr. ... Oventus O2Vent technology. As many as 18 million Americans are estimated to suffer ... Oral appliances can offer significant relief to about 75 percent of people with ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: